Withdrawal Notice: In Drug Repurposing Tactics against Covid-19

Abstract

Background: Now a days, due to high substantial costs and slow rate of new drug discovery and development, repurposing of old drugs to treat diseases is becoming an emerging drug approach. Repurposing approach involves the identification of new pharmacological activity for old drugs. This strategy is time saving, more effective and has lesser failure risks. Methods: The present review involves the challenge by summarising the COVID‐19 drug repurposing research into three large groups, including repurposing of Antivirals, Anti-Cancer Drugs, existing Quinoline based drugs. Results: Number of medications, for example remdesivir, umifenovir, favipiravin, ribavirin, rapamycin, carfilzomib, chloroquine and hydroxychloroquine, saquinavir, elvitegravir, and oxolinic acid and rilapladib have indicated inhibitory effects against the SARS-CoV2 in vitro just as in clinical conditions. These medications either act through infection related targets, for example, RNA genome, polypeptide pressing and take-up pathways or target have related pathways including angiotensin-changing over protein 2 (ACE2) receptors also, inflammatory pathways. Conclusion: From the literature studies it can be concluded that, In the current scenario repositioning of the drugs could be considered the new avenue for the treatment of COVID-19.